76
|
Geng AL, Xu SF, Zhang Y, Zhang J, Chu Q, Liu HG. Effects of photoperiod on broodiness, egg-laying and endocrine responses in native laying hens. Br Poult Sci 2014; 55:264-9. [PMID: 24404878 DOI: 10.1080/00071668.2013.878782] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
1. The effects of photoperiod on broodiness, egg-laying and endocrine responses in native laying hens were investigated. A total of 648, 18-week-old native laying hens (Beijing You Chicken, BYC) were randomly allocated to 6 groups with 3 replicates. The birds were exposed to 1 of 6 different photoperiods, including 16L:8D (06:00 to 22:00 h) for group 1; 12L:2D:4L:6D for group 2; 8L:4D:4L:8D for group 3; 16L:8D (03:00 to 19:00 h) for group 4; 14L:10D for group 5; and 18L:6D for group 6. 2. The broodiness rate and egg-laying rate for weeks 20-26, 27-33, 34-40, 41-47, 48-54 and 55-61 were calculated, and serum prolactin (PRL), luteinising hormone (LH), 17-beta-oestradiol (E2), melatonin (Mel) and progesterone (P4) concentrations were measured at the end of each stage. 3. Significant effects were observed on the rate of broodiness by the photoperiod and stage, but the interaction of photoperiod and stage was not significant. The rate of broodiness for group 3 (5.9%) was significantly higher than other groups, with group 2 being the lowest (2.8%). Broodiness rate was the highest for weeks 41-47 (9.9%). Significant effects were observed on average egg-laying rate by photoperiod and stage: the rate of egg-laying of groups 2 and 5 were significantly higher than groups 1, 4 and 6. 4. There were no significant effects of photoperiod on PRL, LH and Mel concentrations at 26, 33, 40 and 54 weeks of age (P > 0.05), but at 47 weeks of age, PRL and LH concentrations of group 1 were significantly lower than those in other groups. 5. The study suggests that the photoperiod of group 2 (12L:2D:4L:6D) is optimal for the birds' performance to give the lowest broodiness rate and the highest egg-laying rate during the whole laying period, and 41-47 weeks may be a key stage for the photomodulation of broodiness.
Collapse
|
77
|
Aasi J, Abadie J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Accadia T, Acernese F, Adams C, Adams T, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ajith P, Allen B, Allocca A, Amador Ceron E, Amariutei D, Anderson RA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda J, Ast S, Aston SM, Astone P, Aufmuth P, Aulbert C, Austin L, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barker D, Barnum SH, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch J, Bauchrowitz J, Bauer TS, Bebronne M, Behnke B, Bejger M, Beker MG, Bell AS, Bell C, Belopolski I, Bergmann G, Berliner JM, Bersanetti D, Bertolini A, Bessis D, Betzwieser J, Beyersdorf PT, Bhadbhade T, Bilenko IA, Billingsley G, Birch J, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Blom M, Bock O, Bodiya TP, Boer M, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bowers J, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brannen CA, Brau JE, Breyer J, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Brown DD, Brückner F, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Calderón Bustillo J, Calloni E, Camp JB, Campsie P, Cannon KC, Canuel B, Cao J, Capano CD, Carbognani F, Carbone L, Caride S, Castiglia A, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chakraborty R, Chalermsongsak T, Chao S, Charlton P, Chassande-Mottin E, Chen X, Chen Y, Chincarini A, Chiummo A, Cho HS, Chow J, Christensen N, Chu Q, Chua SSY, Chung S, Ciani G, Clara F, Clark DE, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Colombini M, Constancio M, Conte A, Conte R, Cook D, Corbitt TR, Cordier M, Cornish N, Corsi A, Costa CA, Coughlin MW, Coulon JP, Countryman S, Couvares P, Coward DM, Cowart M, Coyne DC, Craig K, Creighton JDE, Creighton TD, Crowder SG, Cumming A, Cunningham L, Cuoco E, Dahl K, Dal Canton T, Damjanic M, Danilishin SL, D'Antonio S, Danzmann K, Dattilo V, Daudert B, Daveloza H, Davier M, Davies GS, Daw EJ, Day R, Dayanga T, De Rosa R, Debreczeni G, Degallaix J, Del Pozzo W, Deleeuw E, Deléglise S, Denker T, Dent T, Dereli H, Dergachev V, DeRosa R, DeSalvo R, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Virgilio A, Díaz M, Dietz A, Dmitry K, Donovan F, Dooley KL, Doravari S, Drago M, Drever RWP, Driggers JC, Du Z, Dumas JC, Dwyer S, Eberle T, Edwards M, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Endrőczi G, Essick R, Etzel T, Evans K, Evans M, Evans T, Factourovich M, Fafone V, Fairhurst S, Fang Q, Farinon S, Farr B, Farr W, Favata M, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fisher R, Flaminio R, Foley E, Foley S, Forsi E, Fotopoulos N, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Fritschel P, Frolov VV, Fujimoto MK, Fulda P, Fyffe M, Gair J, Gammaitoni L, Garcia J, Garufi F, Gehrels N, Gemme G, Genin E, Gennai A, Gergely L, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gil-Casanova S, Gill C, Gleason J, Goetz E, Goetz R, Gondan L, González G, Gordon N, Gorodetsky ML, Gossan S, Goßler S, Gouaty R, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Griffo C, Groot P, Grote H, Grover K, Grunewald S, Guidi GM, Guido C, Gushwa KE, Gustafson EK, Gustafson R, Hall B, Hall E, Hammer D, Hammond G, Hanke M, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Hartman MT, Haughian K, Hayama K, Heefner J, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Heptonstall AW, Heurs M, Hild S, Hoak D, Hodge KA, Holt K, Holtrop M, Hong T, Hooper S, Horrom T, Hosken DJ, Hough J, Howell EJ, Hu Y, Hua Z, Huang V, Huerta EA, Hughey B, Husa S, Huttner SH, Huynh M, Huynh-Dinh T, Iafrate J, Ingram DR, Inta R, Isogai T, Ivanov A, Iyer BR, Izumi K, Jacobson M, James E, Jang H, Jang YJ, Jaranowski P, Jiménez-Forteza F, Johnson WW, Jones D, Jones DI, Jones R, Jonker RJG, Ju L, K H, Kalmus P, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Kasprzack M, Kasturi R, Katsavounidis E, Katzman W, Kaufer H, Kaufman K, Kawabe K, Kawamura S, Kawazoe F, Kéfélian F, Keitel D, Kelley DB, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim BK, Kim C, Kim K, Kim N, Kim W, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kline J, Koehlenbeck S, Kokeyama K, Kondrashov V, Koranda S, Korth WZ, Kowalska I, Kozak D, Kremin A, Kringel V, Królak A, Kucharczyk C, Kudla S, Kuehn G, Kumar A, Kumar P, Kumar R, Kurdyumov R, Kwee P, Landry M, Lantz B, Larson S, Lasky PD, Lawrie C, Lazzarini A, Le Roux A, Leaci P, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee J, Lee J, Leonardi M, Leong JR, Leroy N, Letendre N, Levine B, Lewis JB, Lhuillier V, Li TGF, Lin AC, Littenberg TB, Litvine V, Liu F, Liu H, Liu Y, Liu Z, Lloyd D, Lockerbie NA, Lockett V, Lodhia D, Loew K, Logue J, Lombardi AL, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Luan J, Lubinski MJ, Lück H, Lundgren AP, Macarthur J, Macdonald E, Machenschalk B, MacInnis M, Macleod DM, Magana-Sandoval F, Mageswaran M, Mailand K, Majorana E, Maksimovic I, Malvezzi V, Man N, Manca GM, Mandel I, Mandic V, Mangano V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Martinelli L, Martynov D, Marx JN, Mason K, Masserot A, Massinger TJ, Matichard F, Matone L, Matzner RA, Mavalvala N, May G, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIver J, Meacher D, Meadors GD, Mehmet M, Meidam J, Meier T, Melatos A, Mendell G, Mercer RA, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Mikhailov EE, Milano L, Miller J, Minenkov Y, Mingarelli CMF, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohapatra SRP, Mokler F, Moraru D, Moreno G, Morgado N, Mori T, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Mukherjee S, Mullavey A, Munch J, Murphy D, Murray PG, Mytidis A, Nagy MF, Nanda Kumar D, Nardecchia I, Nash T, Naticchioni L, Nayak R, Necula V, Nelemans G, Neri I, Neri M, Newton G, Nguyen T, Nishida E, Nishizawa A, Nitz A, Nocera F, Nolting D, Normandin ME, Nuttall LK, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oppermann P, O'Reilly B, Ortega Larcher W, O'Shaughnessy R, Osthelder C, Ott CD, Ottaway DJ, Ottens RS, Ou J, Overmier H, Owen BJ, Padilla C, Pai A, Palomba C, Pan Y, Pankow C, Paoletti F, Paoletti R, Papa MA, Paris H, Pasqualetti A, Passaquieti R, Passuello D, Pedraza M, Peiris P, Penn S, Perreca A, Phelps M, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pinard L, Pindor B, Pinto IM, Pitkin M, Poeld J, Poggiani R, Poole V, Poux C, Predoi V, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Quintero E, Quitzow-James R, Raab FJ, Rabeling DS, Rácz I, Radkins H, Raffai P, Raja S, Rajalakshmi G, Rakhmanov M, Ramet C, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Robertson NA, Robinet F, Rocchi A, Roddy S, Rodriguez C, Rodruck M, Roever C, Rolland L, Rollins JG, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Salemi F, Sammut L, Sandberg V, Sanders J, Sannibale V, Santiago-Prieto I, Saracco E, Sassolas B, Sathyaprakash BS, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield RMS, Schreiber E, Schuette D, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock D, Shah S, Shahriar MS, Shaltev M, Shapiro B, Shawhan P, Shoemaker DH, Sidery TL, Siellez K, Siemens X, Sigg D, Simakov D, Singer A, Singer L, Sintes AM, Skelton GR, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith RJE, Smith-Lefebvre ND, Soden K, Son EJ, Sorazu B, Souradeep T, Sperandio L, Staley A, Steinert E, Steinlechner J, Steinlechner S, Steplewski S, Stevens D, Stochino A, Stone R, Strain KA, Straniero N, Strigin S, Stroeer AS, Sturani R, Stuver AL, Summerscales TZ, Susmithan S, Sutton PJ, Swinkels B, Szeifert G, Tacca M, Talukder D, Tang L, Tanner DB, Tarabrin SP, Taylor R, ter Braack APM, Thirugnanasambandam MP, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari V, Tokmakov KV, Tomlinson C, Toncelli A, Tonelli M, Torre O, Torres CV, Torrie CI, Travasso F, Traylor G, Tse M, Ugolini D, Unnikrishnan CS, Vahlbruch H, Vajente G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Heijningen J, van Veggel AA, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Verma S, Vetrano F, Viceré A, Vincent-Finley R, Vinet JY, Vitale S, Vlcek B, Vo T, Vocca H, Vorvick C, Vousden WD, Vrinceanu D, Vyachanin SP, Wade A, Wade L, Wade M, Waldman SJ, Walker M, Wallace L, Wan Y, Wang J, Wang M, Wang X, Wanner A, Ward RL, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wibowo S, Wiesner K, Wilkinson C, Williams L, Williams R, Williams T, Willis JL, Willke B, Wimmer M, Winkelmann L, Winkler W, Wipf CC, Wittel H, Woan G, Worden J, Yablon J, Yakushin I, Yamamoto H, Yancey CC, Yang H, Yeaton-Massey D, Yoshida S, Yum H, Yvert M, Zadrożny A, Zanolin M, Zendri JP, Zhang F, Zhang L, Zhao C, Zhu H, Zhu XJ, Zotov N, Zucker ME, Zweizig J. Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors. PHYSICAL REVIEW LETTERS 2014; 112:131101. [PMID: 24745400 DOI: 10.1103/physrevlett.112.131101] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Indexed: 06/03/2023]
Abstract
Cosmic strings can give rise to a large variety of interesting astrophysical phenomena. Among them, powerful bursts of gravitational waves (GWs) produced by cusps are a promising observational signature. In this Letter we present a search for GWs from cosmic string cusps in data collected by the LIGO and Virgo gravitational wave detectors between 2005 and 2010, with over 625 days of live time. We find no evidence of GW signals from cosmic strings. From this result, we derive new constraints on cosmic string parameters, which complement and improve existing limits from previous searches for a stochastic background of GWs from cosmic microwave background measurements and pulsar timing data. In particular, if the size of loops is given by the gravitational backreaction scale, we place upper limits on the string tension Gμ below 10(-8) in some regions of the cosmic string parameter space.
Collapse
|
78
|
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, Silber J, Harinath G, Chan TA, Huse JT, Anai S, Hide T, Nakamura H, Makino K, Yano S, Kuratsu JI, Balyasnikova IV, Prasol MS, Kanoija DK, Aboody KS, Lesniak MS, Barone T, Burkhart C, Purmal A, Gudkov A, Gurova K, Plunkett R, Barton K, Misuraca K, Cordero F, Dobrikova E, Min H, Gromeier M, Kirsch D, Becher O, Pont LB, Kloezeman J, van den Bent M, Kanaar R, Kremer A, Swagemakers S, French P, Dirven C, Lamfers M, Leenstra S, Pont LB, Balvers R, Kloezeman J, Kleijn A, Lawler S, Leenstra S, Dirven C, Lamfers M, Gong X, Andres A, Hanson J, Delashaw J, Bota D, Chen CC, Yao NW, Chuang WJ, Chang C, Chen PY, Huang CY, Wei KC, Cheng Y, Dai Q, Morshed R, Han Y, Auffinger B, Wainwright D, Zhang L, Tobias A, Rincon E, Thaci B, Ahmed A, He C, Lesniak M, Choi YA, Pandya H, Gibo DM, Fokt I, Priebe W, Debinski W, Chornenkyy Y, Agnihotri S, Buczkowicz P, Rakopoulos P, Morrison A, Barszczyk M, Becher O, Hawkins C, Chung S, Decollogne S, Luk P, Shen H, Ha W, Day B, Stringer B, Hogg P, Dilda P, McDonald K, Moore S, Hayden-Gephart M, Bergen J, Su Y, Rayburn H, Edwards M, Scott M, Cochran J, Das A, Varma AK, Wallace GC, Dixon-Mah YN, Vandergrift WA, Giglio P, Ray SK, Patel SJ, Banik NL, Dasgupta T, Olow A, Yang X, Mueller S, Prados M, James CD, Haas-Kogan D, Dave ND, Desai PB, Gudelsky GA, Chow LML, LaSance K, Qi X, Driscoll J, Driscoll J, Ebsworth K, Walters MJ, Ertl LS, Wang Y, Berahovic RD, McMahon J, Powers JP, Jaen JC, Schall TJ, Eroglu Z, Portnow J, Sacramento A, Garcia E, Raubitschek A, Synold T, Esaki S, Rabkin S, Martuza R, Wakimoto H, Ferluga S, Tome CL, Debinski W, Forde HE, Netland IA, Sleire L, Skeie B, Enger PO, Goplen D, Giladi M, Tichon A, Schneiderman R, Porat Y, Munster M, Dishon M, Weinberg U, Kirson E, Wasserman Y, Palti Y, Giladi M, Porat Y, Schneiderman R, Munster M, Weinberg U, Kirson E, Palti Y, Gramatzki D, Staudinger M, Frei K, Peipp M, Weller M, Grasso C, Liu L, Becher O, Berlow N, Davis L, Fouladi M, Gajjar A, Hawkins C, Huang E, Hulleman E, Hutt M, Keller C, Li XN, Meltzer P, Quezado M, Quist M, Raabe E, Spellman P, Truffaux N, van Vurden D, Wang N, Warren K, Pal R, Grill J, Monje M, Green AL, Ramkissoon S, McCauley D, Jones K, Perry JA, Ramkissoon L, Maire C, Shacham S, Ligon KL, Kung AL, Zielinska-Chomej K, Grozman V, Tu J, Viktorsson K, Lewensohn R, Gupta S, Mladek A, Bakken K, Carlson B, Boakye-Agyeman F, Kizilbash S, Schroeder M, Reid J, Sarkaria J, Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS, Hashizume R, Tom M, Ihara Y, Ozawa T, Santos R, Torre JDL, Lepe E, Waldman T, Prados M, James D, Hashizume R, Ihara Y, Huang X, Yu-Jen L, Tom M, Mueller S, Gupta N, Solomon D, Waldman T, Zhang Z, James D, Hayashi T, Adachi K, Nagahisa S, Hasegawa M, Hirose Y, Gephart MH, Moore S, Bergen J, Su YS, Rayburn H, Scott M, Cochran J, Hingtgen S, Kasmieh R, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Fisher P, Shah K, Horne E, Diaz P, Stella N, Huang C, Yang H, Wei K, Huang T, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibanez C, Kasahara N, Gunzburg W, Gruber H, Pertschuk D, Jolly D, Robbins J, Hurwitz B, Yoo JY, Bolyard C, Yu JG, Wojton J, Zhang J, Bailey Z, Eaves D, Cripe T, Old M, Kaur B, Serwer L, Yoshida Y, Le Moan N, Santos R, Ng S, Butowski N, Krtolica A, Ozawa T, Cary SPL, James CD, Johns T, Greenall S, Donoghue J, Adams T, Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Wirtz CR, Debatin KM, Halatsch ME, Karpel-Massler G, Kast RE, Westhoff MA, Merkur N, Dwucet A, Wirtz CR, Debatin KM, Halatsch ME, Kievit F, Stephen Z, Wang K, Kolstoe D, Silber J, Ellenbogen R, Zhang M, Kitange G, Schroeder M, Sarkaria J, Kleijn A, Haefner E, Leenstra S, Dirven C, Lamfers M, Knubel K, Pernu BM, Sufit A, Pierce AM, Nelson SK, Keating AK, Jensen SS, Kristensen BW, Lachowicz J, Demeule M, Regina A, Tripathy S, Curry JC, Nguyen T, Castaigne JP, Le Moan N, Serwer L, Yoshida Y, Ng S, Davis T, Santos R, Davis A, Tanaka K, Keating T, Getz J, Kapp GT, Romero JM, Ozawa T, James CD, Krtolica A, Cary SPL, Lee S, Ramisetti S, Slagle-Webb B, Sharma A, Connor J, Lee WS, Maire C, Kluk M, Aster JC, Ligon K, Sun S, Lee D, Ho ASW, Pu JKS, Zhang ZQ, Lee NP, Day PJR, Leung GKK, Liu Z, Liu X, Madhankumar AB, Miller P, Webb B, Connor JR, Yang QX, Lobo M, Green S, Schabel M, Gillespie Y, Woltjer R, Pike M, Lu YJ, Torre JDL, Waldman T, Prados M, Ozawa T, James D, Luchman HA, Stechishin O, Nguyen S, Cairncross JG, Weiss S, Lun X, Wells JC, Hao X, Zhang J, Grinshtein N, Kaplan D, Luchman A, Weiss S, Cairncross JG, Senger D, Robbins S, Madhankumar A, Slagle-Webb B, Rizk E, Payne R, Park A, Pang M, Harbaugh K, Connor J, Wilisch-Neumann A, Pachow D, Kirches E, Mawrin C, McDonell S, Liang J, Piao Y, Nguyen N, Yung A, Verhaak R, Sulman E, Stephan C, Lang F, de Groot J, Mizobuchi Y, Okazaki T, Kageji T, Kuwayama K, Kitazato KT, Mure H, Hara K, Morigaki R, Matsuzaki K, Nakajima K, Nagahiro S, Kumala S, Heravi M, Devic S, Muanza T, Nelson SK, Knubel KH, Pernu BM, Pierce AM, Keating AK, Neuwelt A, Nguyen T, Wu YJ, Donson A, Vibhakar R, Venkatamaran S, Amani V, Neuwelt E, Rapkin L, Foreman N, Ibrahim F, New P, Cui K, Zhao H, Chow D, Stephen W, Nozue-Okada K, Nagane M, McDonald KL, Ogawa D, Chiocca E, Godlewski J, Ozawa T, Yoshida Y, Santos R, James D, Pang M, Liu X, Madhankumar AB, Slagle-Webb B, Patel A, Miller P, Connor J, Pasupuleti N, Gorin F, Valenzuela A, Leon L, Carraway K, Ramachandran C, Nair S, Quirrin KW, Khatib Z, Escalon E, Melnick S, Phillips A, Boghaert E, Vaidya K, Ansell P, Shalinsky D, Zhang Y, Voorbach M, Mudd S, Holen K, Humerickhouse R, Reilly E, Huang T, Parab S, Diago O, Espinoza FL, Martin B, Ibanez C, Kasahara N, Gruber H, Pertschuk D, Jolly D, Robbins J, Ryken T, Agarwal S, Al-Keilani M, Alqudah M, Sibenaller Z, Assemolt M, Sai K, Li WY, Li WP, Chen ZP, Saito R, Sonoda Y, Kanamori M, Yamashita Y, Kumabe T, Tominaga T, Sarkar G, Curran G, Jenkins R, Scharnweber R, Kato Y, Lin J, Everson R, Soto H, Kruse C, Kasahara N, Liau L, Prins R, Semenkow S, Chu Q, Eberhart C, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Serwer L, Kapp GT, Le Moan N, Yoshida Y, Romero JM, Ng S, Davis A, Ozawa T, Krtolica A, James CD, Cary SPL, Shai R, Pismenyuk T, Moshe I, Fisher T, Freedman S, Simon A, Amariglio N, Rechavi G, Toren A, Yalon M, Shen H, Decollogne S, Dilda P, Chung S, Luk P, Hogg P, McDonald K, Shimazu Y, Kurozumi K, Ichikawa T, Fujii K, Onishi M, Ishida J, Oka T, Watanabe M, Nasu Y, Kumon H, Date I, Sirianni RW, McCall RL, Spoor J, van der Kaaij M, Kloezeman J, Geurtjens M, Dirven C, Lamfers M, Leenstra S, Stephen Z, Veiseh O, Kievit F, Fang C, Leung M, Ellenbogen R, Silber J, Zhang M, Strohbehn G, Atsina KK, Patel T, Piepmeier J, Zhou J, Saltzman WM, Takahashi M, Valdes G, Inagaki A, Kamijima S, Hiraoka K, Micewicz E, McBride WH, Iwamoto KS, Gruber HE, Robbins JM, Jolly DJ, Kasahara N, Warren K, McCully C, Bacher J, Thomas T, Murphy R, Steffen-Smith E, McAllister R, Pastakia D, Widemann B, Wei K, Yang H, Huang C, Chen P, Hua M, Liu H, Woolf EC, Abdelwahab MG, Fenton KE, Liu Q, Turner G, Preul MC, Scheck AC, Yoshida Y, Ozawa T, Butowski N, Shen W, Brown D, Pedersen H, James D, Zhang J, Hariono S, Yao TW, Sidhu A, Hashizume R, James CD, Weiss WA, Nicolaides TP, Olusanya T. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY. Neuro Oncol 2013; 15:iii37-iii61. [PMCID: PMC3823891 DOI: 10.1093/neuonc/not176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
79
|
Chu Q, Liu L, Wang W. Overexpression of hCLP46 enhances Notch activation and regulates cell proliferation in a cell type-dependent manner. Cell Prolif 2013; 46:254-62. [PMID: 23692084 DOI: 10.1111/cpr.12037] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2012] [Accepted: 02/02/2013] [Indexed: 01/02/2023] Open
Abstract
OBJECTIVES Human CAP10-like protein 46 kDa (hCLP46), also known as Poglut1, has been shown to be an essential regulator of Notch signalling. hCLP46 is overexpressed in primary acute myelogenous leukaemia, T-acute lymphoblastic leukaemia samples and other leukaemia cell lines. However, effects of hCLP46 overexpression, up to now, have remained unknown. MATERIALS AND METHODS In this study, we established stable 293TRex cell lines inducibly overexpressing hCLP46, and knocked down hCLP6 with a specific small interfering RNA to explore function of the protein in Notch signalling and cell proliferation. RESULTS hCLP46 overexpression enhanced Notch1 activation in 293Trex cells in a ligand-dependent manner, with increased Notch signalling enhancing Hes1 expression. We further verified that overexpression of hCLP46 inhibited proliferation of 293TRexs and was correlated with increases in cyclin dependent kinase inhibitors p21 and p27, whereas reduced hCLP46 expression moderately increased cell proliferation. In addition, p21 and p27 protein levels were higher when Notch signalling was activated by EDTA treatment. CONCLUSIONS Taken together, hCLP46 enhanced Notch activation and inhibited 293TRex cell proliferation through CDKI signalling.
Collapse
|
80
|
Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2013; 21:1501-5. [PMID: 23793364 DOI: 10.1245/s10434-013-3061-z] [Citation(s) in RCA: 133] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2012] [Indexed: 11/18/2022]
Abstract
BACKGROUND The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC. METHODS A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests. RESULTS Response rates for ASPSM members (n = 45) and non-ASPSM members (n = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin. CONCLUSIONS This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow.
Collapse
|
81
|
Kozono D, Nitta M, Sampetrean O, Kimberly N, Kushwaha D, Merzon D, Ligon K, Zhu S, Zhu K, Kim TH, Kwon CH, Becher O, Saya H, Chen CC, Donovan LK, Birks SM, Bosak V, Pilkington GJ, Mao P, Li J, Joshi K, Hu B, Cheng S, Sobol RW, Nakano I, Li M, Hale JS, Myers JT, Huang AY, Gladson C, Sloan AA, Rich JN, Lathia JD, Hall PE, Li M, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MS, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips H, Lai A, Gladson C, Bredel M, Bao S, Hjelmeland A, Lathia JD, Rich JN, Hale JS, Li M, Sinyuk M, Rich JN, Lathia JD, Lathia JD, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Carson CT, Naik U, Hjelmeland A, Majumder S, Rich JN, Venere M, Wu Q, Song LA, Vasanji A, Tenley N, Hjelmeland AB, Rich JN, Peruzzi P, Bronisz A, Antonio Chiocca E, Godlewski JA, Guryanova OA, Wu Q, Fang X, Rich JN, Bao S, Christel HMC, Benito C, Zoltan G, Aline B, Tilman S, Josephine B, Carolin M, Thomas S, Violaine G, Unterberg A, Capilla-Gonzalez V, Guerrero-Cazares H, Cebrian-Silla A, Garcia-Verdugo JM, Quinones-Hinojosa A, Man J, Shoemake J, Venere M, Rich J, Yu J, He X, DiMeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Nguyen SA, Stechishin OD, Luchman HA, Kelly JJ, Cairncross JG, Weiss S, Kim Y, Kim E, Wu Q, Guryanova OO, Hitomi M, Lathia J, Serwanski D, Sloan AE, Robert J, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN, Liu JK, Wu Q, Hjelmeland AB, Rich JN, Flavahan WA, Kim Y, Li M, Lathia J, Rich J, Hjelmeland A, Fernandez N, Wu M, Bredel M, Das S, Bazzoli E, Pulvirenti T, Oberstadt MC, Perna F, Boyoung W, Schultz N, Huse JT, Fomchenko EI, Voza F, Tabar V, Brennan CW, DeAngelis LM, Nimer SD, Holland EC, Squatrito M, Chen YH, Gutmann DH, Kim SH, Lee MK, Chwae YJ, Yoo BC, Kim KH, Soeda A, Hara A, Iwama T, Park DM, Golebiewska A, Bougnaud S, Stieber D, Brons NH, Vallar L, Hertel F, Bjerkvig R, Niclou SP, Hamerlik P, Lathia JD, Rasmussen R, Fricova D, Rich JN, Jiri B, Schulte A, Kathagen A, Zapf S, Meissner H, Phillips HS, Westphal M, Lamszus K, Sanzey M, Golebiewska A, Stieber D, Niclou SP, Singh SK, Vartanian A, Gumin J, Sulman EP, Lang FF, Zadeh G, Bayin NS, Dietrich A, Abel T, Chao MV, Song HR, Buchholz CJ, Placantonakis D, Esencay M, Zagzag D, Balyasnikova IV, Prasol MS, Ferguson SD, Ahmed AU, Han Y, Lesniak MS, Barish ME, Brown CE, Herrmann K, Argalian S, Gutova M, Tang Y, Annala A, Moats RA, Ghoda LY, Aboody KS, Hitomi M, Gallagher J, Gadani S, Li M, Adkins J, Vsanji A, Wu Q, Soeda A, McLendon R, Chenn A, Hjelmeland A, Park D, Lathia J, Rich J, Dictus C, Friauf S, Valous NA, Grabe N, Muerle B, Unterberg AW, Herold-Mende CC, Lee HK, Finniss S, Buchris E, Ziv-Av A, Casacu S, Xiang C, Bobbit K, Rempel SA, Mikkelsen T, Slavin S, Brodie C, Kim E, Woo DH, Oh Y, Kim M, Nam DH, Lee J, Li Q, Salas S, Pendleton C, Wijesekera O, Chesler D, Wang J, Smith C, Guerrero-Cazares H, Levchenko A, Quinones-Hinojosa A, LaPlant Q, Pitter K, Bleau AM, Helmy K, Werbeck J, Barrett L, Shimizu F, Benezra R, Tabar V, Holland E, Chu Q, Bar E, Orr B, Eberhart CG, Schmid RS, Bash RE, Werneke AM, White KK, Miller CR, Agasse F, Jhaveri N, Hofman FM, Chen TC, Natsume A, Wakabayashi T, Kondo Y, Woo DH, Kim E, Chang N, Nam DH, Lee J, Moon E, Kanai R, Yip S, Kimura A, Tanaka S, Rheinbay E, Cahill D, Curry W, Mohapatra G, Iafrate J, Chi A, Martuza R, Rabkin S, Wakimoto H, Cusulin C, Luchman HA, Weiss S, Gutova M, Frank JA, Annala AJ, Barish ME, Moats RA, Aboody KS. LAB-STEM CELLS. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
82
|
Wooddell C, John M, Hossbach M, Deckert J, Hadwiger P, Hamilton H, Chu Q, Wakefield D, Klein J, Vornlocher HP, McLachlan A, Rozema D, Lewis D. RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Int J Infect Dis 2012. [DOI: 10.1016/j.ijid.2012.05.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
83
|
Sun D, Fan X, Xie Y, Chu Q, Sun Y, Zhang Y, Zhang S, Gong W, Chen S, Li Y, Shi W, Zhang Y. Short communication: Distribution of recessive genetic defect carriers in Chinese Holstein. J Dairy Sci 2011; 94:5695-8. [DOI: 10.3168/jds.2011-4345] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2011] [Accepted: 05/25/2011] [Indexed: 11/19/2022]
|
84
|
Sheng A, Lan J, Wu H, Lu J, Wang Y, Chu Q, Jia Z, Song M, Liu L, Wang W. A clinical case-control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. Int J Immunogenet 2011; 37:445-54. [PMID: 20618520 DOI: 10.1111/j.1744-313x.2010.00946.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Mannose-binding lectin (MBL) is a key molecule of the innate immune system and a competent to bind carbohydrates of a variety of microorganisms, resulting in complement activation and opsonophagocytosis against various pathogens. However, there is no systemic investigation on the MBL's role in innate immune responses against HIV-1 infection among northern Han Chinese. This study investigated the association between MBL and HIV-1 infection susceptibility among northern Han Chinese. A total of 91 HIV-1 infected patients and 91 HIV-1 seronegative healthy individuals were recruited. Six polymorphisms of MBL2 gene were genotyped by pyrosequencing. The quantitative measurement of serum MBL concentration and MBL complex activity were performed by ELISA. The CD4+ T-cell counts were determined by flow cytometry. The plasma viral loads of 91 HIV-1 infected patients were determined by bDNA method. The results show that there is an association between MBL and HIV-1 infection susceptibility among northern Han Chinese. The individuals with B variant, low serum MBL concentration and low MBL complex activity are more susceptible to HIV-1 infection.
Collapse
|
85
|
Chu Q, Zhang H, Zhang D, Ye J. Analysis of polyphenols inValeriana wallichiiDC by capillary electrophoresis with amperometric detection. ACTA CHROMATOGR 2010. [DOI: 10.1556/achrom.22.2010.4.11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
86
|
Yee D, Butts C, Chu Q, Fenton D, Joy A, Reiman A, Smylie M, Roa W. Phase II Trial of Consolidation Chest Radiotherapy for Extensive Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
87
|
Jiang L, Wang J, He Y, Ye J, Chu Q. Determination of Phenolic Disinfectants in Consumer Products by Capillary Electrophoresis with Amperometric Detection. J Chromatogr Sci 2010; 48:584-8. [DOI: 10.1093/chromsci/48.7.584] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
88
|
Pennington K, Mathis J, Li B, Chu Q. Testing a Tropism-Modified Conditionally Replicative Adenovirus for Breast Cancer in a Tissue Slice Model System. J Surg Res 2010. [DOI: 10.1016/j.jss.2009.11.629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
89
|
Chu Q, Mao X, Chen S, Xing F, Li H, Chen L, Qiu Z, Song Q. UP-3.128: Effect of Spermatozoa Derived from Ejaculation, Epididymis and Testis on Outcome of ICSI. Urology 2009. [DOI: 10.1016/j.urology.2009.07.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
90
|
Yee D, Chu Q, Butts C, Joy A, Fenton D, Smylie M, Reiman A, Roa W. 77 PHASE 1 DOSE ESCALATION TRIAL OF LIMITED FIELD HYPOFRACTIONATED THORACIC RADIOTHERAPY FOR LIMITED STAGE SMALL CELL LUNG CANCER. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)72464-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
91
|
von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A. Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10579 Background: AZD0530 is a novel oral anilino quinazoline that is selective for c-Src, c-Yes, Lck, and Bcr-Abl through ATP competitive and reversible inhibition of the target enzyme. Src kinases play a role in tumor cell migration, invasion and metastasis as well as being part of the signaling cascade for angiogenesis and growth factors. Advanced STS have limited therapeutic options; therefore we tested the efficacy of AZD0530 in advanced STS. Methods: The study utilized a Simon Two stage design with the primary endpoint be objective tumor response + prolonged stable disease rate (defined as partial/complete response by RECIST, or stable disease >4 months). Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent. Patients were excluded for cardiac dysfunction, poorly controlled hypertension, inability to swallow or absorb medication. Patients had pulmonary function tests at baseline that were repeated within the first 4 weeks of therapy. Results: 17 patients (11 F, 6M) with advanced STS (leiomyosarcoma 5, rhabdomyosarcoma 3, MFH/carcinosarcoma/Fibrosarcoma 2, endometrial stromal sarcoma/liposarcoma/non-rhabdoSTS 1 each) were enrolled, the majority of whom had prior therapy (14 chemo and 9 xrt). Five continue on study. Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request. Median time to progression in the 13 patients was 1.7 months. Possibly related severe adverse events (all grade 3) included fatigue (2), anemia/lymphopenia/hypokalemia (1 each). To date no confirmed responses have been seen. No drug related pulmonary toxicity has been observed. Conclusions: AZD0530 can be administered safely as a single agent in patients with a variety of advanced STS. To date, tumor responses have not been noted; however patients were not selected based on tumor target expression. Further testing may be warranted in selected tumors in combination with chemotherapy given pre-clinical synergy data or in tumors pre-selected for target expression. No significant financial relationships to disclose.
Collapse
|
92
|
Hiller D, Chu Q, Panu L, Meschonat C, Burton G, Li B. 193. Reduction in EIF4E Level Correlates With Improved Breast Cancer Outcome in Patients Treated With Neoadjuvant Chemotherapy. J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
93
|
Holm NT, Byrnes K, MacDonald M, Abreo F, Ampil F, Sanders M, Burton GV, Li B, Chu Q. Overexpression of chemokine receptor CXCR4 in cancer specimens following neoadjuvant chemotherapy predicts outcome in patients with locally advanced breast cancer (LABC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10578] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10578 Background: Despite significant advances made in the treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy, a significant number of patients continue to die. A molecular predictor to identify those who are at an increased risk for relapse is sorely needed. CXCR4 is a chemokine receptor that has been linked to breast cancer invasion and metastasis. We postulate that CXCR4 overexpression levels in cancer specimens following neoadjuvant chemotherapy predict cancer outcome in patients with LABC. Methods: 54 patients with LABC were prospectively accrued and analyzed. All had neoadjuvant chemotherapy, followed by definitive surgical and adjuvant chemo-radiation therapy. Study homogeneity was maintained by standardized treatment, surveillance, and compliance protocols. A 1 cm 3 cancer from the surgical specimens of each patient was retrieved for analysis. CXCR4 levels were detected using Western blots and results were quantified against 1 μg of HeLa cells (positive controls). CXCR4 expression was defined as low (<6.6 fold) or high (= 6.6 fold). Primary endpoints were cancer recurrence and death. Statistical analysis performed included Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazard model. Results: With a median follow-up of 30 months, patients whose tumors had high CXCR4 overexpression (= 6.6 fold) had a statistically significantly higher incidence of recurrence (p= 0.0009) and cancer-related death (p= 0.0168) than those in the low CXCR4 group (< 6.6 fold). After adjusting for tumor size, nodal status, ER, PR and HER-2 status, the relative risk for recurrence and death in the high CXCR4 group was 27.3-fold (p=0.001; 95% CI: 6.2 to 120.8) and 4.8-fold (p=0.0076; 95% CI: 1.5 to 15.0) higher than those in the low CXCR4 group, respectively. Conclusion: High CXCR4 overexpression in cancer specimens following neoadjuvant chemotherapy was highly predictive of cancer recurrence and cancer death in patients with LABC. No significant financial relationships to disclose.
Collapse
|
94
|
Takimoto CH, Ricart A, Mita M, Mita AC, Chu Q, Tolcher AW, Sarantopoulos J, Mita A, Rowinsky EK. Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2513] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2513 Background: The nucleoside 3’-C-ethynylcytidine (TAS-106) is metabolized in cancer cells to ethynylcytidine triphosphate (ECTP), an inhibitor of RNA polymerases I, II, and III. TAS-106 has potent anticancer activity in broad range of human tumor xenografts. In prior clinical studies, bolus intravenous (IV) TAS-106 caused reversible dose-limiting peripheral neuropathy and the recommended phase II dose (RP2D) was 4.21 mg/m2 every 3 wks. Myelosuppression, asthenia, and mild nausea and vomiting were also common. In rats, 24-h TAS-106 infusions are better tolerated with equivalent efficacy. Therefore, a Phase I study of 24-h infusions of TAS-106 was initiated. Methods: Escalating doses TAS-106 infused over 24-h every 3 wks were administered to cancer patients with pharmacokinetic (PK) monitoring during the initial cycle. Toxicity and response were assessed using NCI CTC (v2) grade (gr) and RECIST, respectively. Plasma and urine TAS-106 concentrations were monitored using LC/MS/MS methods. Results: Overall, 33 pts were treated at the following dose levels: 2.82 (4 pts), 3.5 (5 pts), 4.38 (6 pts), 5.48 (4 pts) 6.85 (6 pts) and 8.56 mg/m2 (8 pts). At 8.56 mg/m2, 2 of 5 pts experienced neutropenic DLTs (febrile neutropenia and gr 4 neutropenia lasting greater than or equal to 3 days) No neuropathy DLTs were observed. At 6.85 mg/m2, gr 3 peripheral neuropathy in cycle 1 was observed in 1 patient, but no other DLTs occurred in 5 patients. Other common drug related toxicities occurring in any cycle included gr 1–2 fatigue (13 pts), gr 3–4 neutropenia (10 pts), gr 1 hand/foot syndrome (9 pts), gr 2–3 anemia (9 pts) gr 1 rash/skin exfoliation (10 pts), and peripheral neuropathy gr 1–2 (5 pts). No objective responses were seen; although 3 pts with parotid, adenoid cystic, and breast cancers demonstrated stable disease for 5, 6, and 7 months, respectively. Plasma concentrations increased with increasing dose, and at 6.85 mg/m2, the Cmax was 77.4±7.3 ng/mL, AUC 1,892±54 ng·h/mL, CL 102±13 mL/h/kg, VDss 1.37±.05 L/kg, and t1/2 was 9.85±1.47 h. Over 48 h, 62.1% of the administered dose of TAS-106 was excreted into the urine. Conclusions: Compared with bolus dosing, 24-h infusions of TAS-106 are better tolerated with less peripheral neuropathy. The RP2D for TAS-106 infused over 24-h every 3 wks is 6.85 mg/m2. [Table: see text]
Collapse
|
95
|
Chu Q, Ling MT, Feng H, Cheung HW, Tsao SW, Wang X, Chuan Wong Y. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis 2007. [DOI: 10.1093/carcin/bgl228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2006. [PMID: 17072675 DOI: 10.1245/s10434-007-9599-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
97
|
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2006; 14:128-33. [PMID: 17072675 DOI: 10.1245/s10434-006-9185-7] [Citation(s) in RCA: 294] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2006] [Revised: 06/02/2006] [Accepted: 06/02/2006] [Indexed: 12/11/2022]
|
98
|
Wable G, Chu Q, Damodaran P, Srihari K. Wave Soldering Using Sn/3.0Ag/0.5Cu Solder and Water Soluble VOC-Free Flux. ACTA ACUST UNITED AC 2006. [DOI: 10.1109/tepm.2006.882500] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
99
|
Papadopoulos KP, Chu Q, Patnaik A, Mita MM, Cooper J, Van Maanen R, Lopez-Lazaro L, Lebedinsky C, Rowinsky EK, Tolcher AW. Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2029 Background: Trabectedin (ET-743) is a DNA minor-groove intercalating agent that blocks transcription factor activity, elicits G2/M cell cycle arrest, and induces apoptosis. Single agent activity has been demonstrated in soft tissue sarcoma (STS), breast, prostate and ovarian cancer. In preclinical studies sequential exposure of paclitaxel (P) followed by trabectedin (T) 24 hrs later resulted in synergy. The objectives of this phase I study were to determine the maximum tolerated dose (MTD) and recommended phase II dose (RD) of sequential P and T administered every 2 weeks in patients with advanced solid tumors. Methods: Escalating doses of P (80–120 mg/m2) over 1hr iv on day 1 and T ( 525–775 μg/m2) as 3 hrs iv day 2 every 2 weeks were administered. To evaluate drug:drug interactions, P was administered alone on day -7 in course 1 and PK studies performed courses 1 & 2. MTD was defined as ≥ 2/3 pts with dose limiting toxicity (DLT) in the 1st 2 courses. Results: 29 pts were enrolled and 27 were evaluable: median age was 48 yrs (19–82). M/F 16/13. Pts were treated over 5 dose levels: I 80/525 (n = 3), II 80/580 (n = 3), III 120/580 (n = 6), IV 120/650 (n = 11), V 120/775 (n = 4). A total of 213 courses of therapy were given, median number of course was 4 (range 1–28). There were 4 DLTs due to neutropenia delaying therapy > 1 week; one each at 120/580 (Grade 2) and 120/650 (Grade 4) and 2 at the MTD of 120/775 (Grade 4). Most common toxicities observed for P+T were neutropenia (24%), nausea (51%), vomiting (24%), transaminitis (23%), myalgia (24%) and alopecia (20%). One pt with PNET has an ongoing CR 16 months, one breast cancer pt (prior P failure) has PR 12 mo+ and 8 pts (6 STS) had SD > 3 mo (range 4–15 mo). There appear to be no marked drug:drug interactions for P and T. Preliminary non-compartmental PK results [geometric mean (CV%)] for T include t1/2 52.4 hr (43.6%); Cl l/hr/m2 31.6 (57.3%); Vss l/m2 1382 (69%) and for P are t1/2, 29.2 hr (39.1%); Cl l/hr/m2 15.3 (44.1%); Vss 213 l/m2 (72%). Conclusions: The recommended dose for this combination is paclitaxel 120 mg/m2 day 1 and trabectedin 650 μg/m2 day 2 administered every 2 weeks. Antitumor activity in STS and breast cancer, predictable PK parameters, and tolerable toxicity warrants further study of this combination. [Table: see text]
Collapse
|
100
|
George BJ, Ricart AD, Calvo E, Chu Q, Sarantopoulos J, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP. Phase I pharmacokinetic(PK)/food effect and safety study of satraplatin in patients (pts) with advanced solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.12014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12014 Background: Satraplatin (S) is a novel oral platinum analog that has demonstrated preliminary activity in hormone refractory prostate cancer (HRPC). A large (950 pts) worldwide, randomized phase III trial evaluating S as 2nd line therapy for HRPC recently completed enrollment. The current study was designed to determine the PKs of S under fasted and fed conditions, as well as treatment efficacy and toxicity. Methods: S was administered orally at 80 mg/m2/day (d) on d1–5 q 35 days, with prophylactic antiemetics. For the 1st cycle, pts were randomized to receive d1 and d5 doses of S in either the fed or fasted state when PK sampling was performed. The fed/fasted state was reversed for the 2nd cycle. Subsequent doses of S were given in the fasted state. Results: 17 pts were enrolled (9M/8F), median age 62 (range 33–78) and tumor types: HRPC (7), breast (3), 1 each with anal, parotid, leiomyosarcoma, Merkel cell, ovarian, mesothelioma, and neuroendocrine tumor. The median no. of prior regimens was 3 (range 1–8). A total of 58 cycles of S were given. Grade 3–4 hematologic toxicities (1st 2 cycles) included: neutropenia (11%), thrombocytopenia (24%) and anemia (24%). The hematologic nadir occurred during week 4. There was no grade 3–4 nausea, vomiting or diarrhea. No significant cardiac, renal, hepatic, or neurologic toxicity was observed. The peak plasma concentration (Cmax) for platinum in plasma ultrafiltrate (PUF) was decreased by 20% when S was administered following a high fat meal compared to the fasting condition. There was no effect of food on AUC0–24 hr. The time of Cmax (Tmax) was delayed in the fed state. Table shows PK parameters. One PR (HRPC) and 4 SD ≥ 5 months (breast, ovarian, parotid and HRPC) were confirmed. Conclusions: There is an effect of food on the Cmax, however the clinical implications are unknown at this time. For this reason, it is recommended that S be administered to pts in the fasting state. At the dose of 80 mg/m2/day, S was well tolerated in this group of heavily pretreated patients. [Table: see text] [Table: see text]
Collapse
|